Open AccessDiagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China
Author(s) -
Wu XiaoYuan,
Hu YangBo,
Li HuiJuan,
Wan Bing,
Zhang ChenXi,
Zhang Bin,
Hu Huan,
Zhang Qun,
Lv TangFeng,
Zhan Ping,
Song Yong
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13722
Subject(s) - medicine , lung cancer , oncology , stage (stratigraphy) , chemotherapy , therapeutic effect , lung , gastroenterology , biology , paleontology
We aimed to compare the diagnostic efficiency of pro GRP and NSE on SCLC and to investigate whether the change of pro GRP level would predict therapeutic response. Patients who were firstly diagnosed pathologically in Nanjing Chest Hospital and measured pro GRP level consecutively were enrolled in the study. Pro GRP level was detected using Elecsys Pro GRP Assay. Totally 75 SCLC , 234 NSCLC and 264 benign lung diseases ( BLD ) were enrolled. Both pro GRP and NSE levels in SCLC were significantly higher than those in NSCLC and BLD , and pro GRP in extensive stage SCLC was higher than which in limited stage ( P ≤ .001). The diagnostic efficiency of pro GRP on SCLC was higher than that of NSE , but when the two biomarkers were bind together, the diagnostic efficiency was the best. When SCLC was differentiated from NSCLC and BLD , the cut‐off values were 114.35 pg/mL and 162.55 pg/mL respectively. For treatment responsive patients, pro GRP level decreased markedly after the first cycle of therapy and kept a continued momentum of decline during treatment. But for unresponsive patients, no obvious decline was observed. Pro GRP had higher diagnostic efficiency on SCLC when compared to NSE , and it could better predict therapeutic response of pulmonary target lesions on chemotherapy.